Panacea Life Sciences Holdings, Inc.

Panacea Life Sciences Holdings, Inc.

PLSH
Panacea Life Sciences Holdings, Inc.US flagOther OTC
0.08
USD
- -
- -
1.59MMarket Cap
2020 Y
2021 Y
2022 Y
2023 Y
TTM
Revenue per Share
0.53
0.12
0.11
0.14
0.25
Basic EPS, GAAP
-0.31
-0.28
-0.62
-0.48
-0.37
Free Cash Flow per Basic Share
-0.64
-0.24
-0.18
-0.1
-0.07
Dividend per Share
- -
- -
- -
- -
- -
Book Value per Share
-0.71
-0.99
-1.74
-2.04
-2.26
Tangible Book Value per Share
0.26
0.29
-0.29
-0.68
-0.91
Basic Weighted Avg Shares
17
17
15
17
17
Sales/Revenue/Turnover
9
2
2
2
4
Operating Margin (%)
-58.31
-269
-347.41
-232.55
-108.65
Depreciation Expense
2
2
2
2
2
Net Income, GAAP
-5
-5
-9
-8
-6
Effective Tax Rate (%)
- -
- -
- -
- -
- -
Profit Margin (%)
-58.02
-232.2
-561.94
-336.08
-150.95
Working Capital
-7
-1
-9
-15
-17
LT Debt
6
7
7
7
7
Total Equity
7
7
-2
-8
-12
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -

Capital Structure

FRC

in mil. unless spec.
Mar'24
Jun'24
Sep'24
ST Debt
15
16
16
LT Borrowings
4
4
4
LT Finance Leases
3
3
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
18
21
21
Market Capitalization
3
3
2

Working Capital

FRC

in mil. unless spec.
Mar'24
Jun'24
Sep'24
Total Current Assets
5
5
5
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
4
4
4
Total Current Liabilities
20
21
22
Payables & Accruals
5
6
6
ST Debt
15
16
16
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
286.63%
Free Cash Flow
- -
- -
-39.86%
Net Income, GAAP
- -
- -
-12.33%
Sales/Revenue/Turnover
- -
- -
46.59%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
1
- -
- -
1
2
2024
- -
- -
1
1
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.12
-0.11
-0.13
- -
-0.48
2024
0.05
- -
-0.06
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Leslie A. Buttorff
Full Time Employees
3
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
5910 South University Boulevard Greenwood Village CO United States of America 80121
IPO Date
Apr 4, 2022
Business
Panacea Life Sciences Holdings, Inc. (PLSH) operates as a diversified life sciences company focused on developing and commercializing innovative cannabinoid-based products and wellness solutions. The company offers a broad portfolio of hemp-derived CBD and minor cannabinoid products, including full-spectrum oils, broad-spectrum tinctures, isolates, topicals, beverages, edibles, and pet products under brands such as Halo, Leafwell, and Elevate; it also provides white-label manufacturing services, custom formulation development, and regulatory-compliant extraction processes for the wellness, nutraceutical, and functional food sectors. Headquartered in Golden, Colorado, Panacea Life Sciences was founded in 2011 and maintains operations primarily in the United States, with distribution reaching retail, e-commerce, and B2B customers across North America. In the past two years, the company has pursued strategic expansions, including a key partnership with a leading national distributor to enhance product availability in major retail chains and the launch of its Elevate brand featuring minor cannabinoid-infused functional beverages targeting the health and wellness market. Panacea Life Sciences completed a significant funding round in late 2024 to scale its cGMP-certified manufacturing facility and invested in advanced CO2 extraction technology for higher-purity cannabinoid isolates. These initiatives support its shift toward international market entry in Europe and Canada, alongside the acquisition of a complementary pet wellness subsidiary to broaden its consumer product lines.

Company News

APIChatGPT
  • Panacea Life Sciences Holdings (OTCID: PLSH) and Benivita Inc. Launch Benivita PLSH -- a New Era in Direct-to-Consumer Virtual Benefits

  • Panacea Life Sciences and Sky Wellness Enter Agreement for Licensing, Marketing, Supply and Development of Sky Wellness CBD Products

  • Panacea Life Sciences Holdings, Inc. Completes Acquisition of N7 Enterprises With Eight Natural Health and Wellness Retail and One Distribution Center Locations in the Tampa, Florida area

  • Panacea Life Sciences Holdings, Inc. Continues Growth Trajectory with Acquisition of the PÜR LIFE Medical Franchise

  • Panacea Life Sciences Holdings, Inc. Celebrates National CBD Day (August 8th) By Shifting To An “Everyday Low Pricing Model” To Meet Customer Needs

  • Panacea Life Sciences Holdings, Inc. Continues Pursuit of High Growth Health and Wellness Products with Acquisition of Sierra Sage, LLC and Halucenex from Melodial Global Health (formerly Creso Pharma Limited)

  • Panacea Life Sciences Holdings, Inc. Announces CBD/CBG Clinical Trial Findings for the Management of Irritable Bowel Symptoms

  • Panacea Life Sciences Holdings, Inc. Chief Scientific Officer, Dr. James Baumgartner, is Featured on The Stock Day Podcast

  • Panacea Life Sciences Holdings, Inc. Chief Scientific Officer, Dr. James Baumgartner, is Featured on The Stock Day Podcast

  • Panacea Life Sciences Holdings, Inc. Enters Into Agreement to Natural Health and Wellness Chain of Retail Locations in Tampa, Florida

  • Panacea Life Sciences Holdings, Inc. Adopts Diversification Plan: Vegan, Organic, Nutraceuticals, Alternative Health and Wellness Products and Investigative Research Plans for Psylocibin and other Psychedelics.

  • Executives Buy Over $1.5M Of 4 Penny Stocks

  • Panacea Life Sciences Ready To Launch CBD And CBG Products In Brazil

  • Panacea Life Sciences, Inc. Announces Exclusive Partnership with Amazon Platform Partner Bright Ideas Unlimited, LLC

  • New Kid In Town — Cannabis Daily December 9, 2021